Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14387482 | 0.97 | MEN1 (0.50) | GPR119ACHEPOLBMEN1KMT2A | |
| SCHEMBL15879042 | 0.97 | MEN1 (0.50) | GPR119ACHEPOLBMEN1KMT2A | |
| SCHEMBL12455887 | 0.92 | GPR119 (0.45) | GPR119ACHEPOLBMEN1KMT2A | |
| SCHEMBL909718 | 0.89 | USP2 (0.56) | MEN1KMT2AMAPTALDH1A1LMNA | |
| SCHEMBL10297496 | 0.89 | GPR119 (0.55) | GPR119ACHEMEN1KMT2ACKS1B | |
| SCHEMBL23175116 | 0.86 | MEN1 (0.47) | GPR119ACHEPOLBMEN1KMT2A | |
| SCHEMBL24851896 | 0.85 | GPR119 (0.50) | GPR119ACHEPOLBMEN1KMT2A | |
| SCHEMBL2015190 | 0.85 | ACHE (0.51) | GPR119ACHEPOLBMEN1KMT2A | |
| SCHEMBL1408638 | 0.84 | GPR119 (0.45) | GPR119ACHEPOLBMEN1KMT2A | |
| SCHEMBL23505759 | 0.83 | SORD (0.37) | GPR119ACHEPOLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497407-B2 | Treatment of skin disorders | TORQUR AG (CH) | 2025-12-16 | — | — | US | disclosed |
| CN-119701002-A | Antibody drug conjugate, pharmaceutical composition and application thereof | 四川科伦博泰生物医药股份有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-119455000-A | Triazine compound, conjugate thereof, preparation method and application | 四川科伦博泰生物医药股份有限公司 | 2025-02-18 | — | — | CN | disclosed |
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2024-11-21 | — | — | US | disclosed |
| US-20240343718-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | TORQUR AG (CH) | 2024-10-17 | — | — | US | disclosed |
| US-11918586-B2 | Treatment of skin lesions | TORQUR AG (CH) | 2024-03-05 | — | — | US | disclosed |
| US-11878972-B2 | Treatment of neurological disorders | TORQUR AG (CH) | 2024-01-23 | — | — | US | disclosed |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-07-06 | — | — | US | disclosed |
| CN-109414415-B | Treatment of skin lesions | 拓客股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| WO-2009035671-A1 | SUBSTITUTED NITROGEN-CONTAINING HETEROARYL DERIVATIVES USEFUL AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-19 | — | — | WO | disclosed |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-03-12 | — | — | US | disclosed |
| US-20070098676-A1 | FUNCTIONALLY DIVERSE MACROMOLECULES AND THEIR SYNTHESIS | THE TEXAS A&M UNIVERSITY SYSTEM | 2007-05-03 | — | — | US | disclosed |
| US-20070098676-A1 | FUNCTIONALLY DIVERSE MACROMOLECULES AND THEIR SYNTHESIS | THE TEXAS A&M UNIVERSITY SYSTEM | 2007-05-03 | — | — | US | disclosed |
| US-20070041933-A1 | Functionally Diverse Macromolecules and Their Synthesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-22 | — | — | US | disclosed |
| US-20070041933-A1 | Functionally Diverse Macromolecules and Their Synthesis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-02-22 | — | — | US | disclosed |
| US-6943162-B2 | Osteoporosis; cardiovascular disorders; anticancer agents;incontinence | SMITHKLINE BEECHAM CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| WO-2005011703-A1 | 2-CYANO-1,3,5-TRIAZINE-4,6-DIAMINE DERIVATIVES | AKZO NOBEL N.V. (NL) | 2005-02-10 | — | — | WO | disclosed |
| US-20040072829-A1 | Piperazinyltriazines as estrogen receptor modulators | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| WO-2002072561-A1 | PIPERAZINYLTRIAZINES AS ESTROGEN RECEPTOR MODULATORS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382496-A1 | TREATMENT OF SKIN LESIONS | C1R, C3AR1, CXCR3 | GPR119 2044/4885ACHE 2220/4885POLB 2558/4885 |
| US-20090069305-A1 | Substituted nitrogen-containing heteroaryl derivatives useful as modulators of the histamine H4 receptor | HRH4, HRH3, HRH2 | GPR119 300/4885ACHE 1303/4885POLB 4593/4885 |
| US-20240343718-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | CHRM2, CHRM1, C1R | GPR119 1052/4885ACHE 183/4885POLB 4257/4885 |
| US-11878972-B2 | Treatment of neurological disorders | CHRM1, CHRM2, C1R | GPR119 1629/4885ACHE 104/4885POLB 3838/4885 |
| US-20070041933-A1 | Functionally Diverse Macromolecules and Their Synthesis | ECPAS, PCNA, MRPS22 | GPR119 4287/4885ACHE 3345/4885POLB 333/4885 |
| US-12497407-B2 | Treatment of skin disorders | RXFP3, CCR3, CBR3 | GPR119 1990/4885ACHE 4210/4885POLB 2800/4885 |
| US-11918586-B2 | Treatment of skin lesions | C1R, C3AR1, CXCR3 | GPR119 2044/4885ACHE 2220/4885POLB 2558/4885 |
| US-20070098676-A1 | FUNCTIONALLY DIVERSE MACROMOLECULES AND THEIR SYNTHESIS | ECPAS, PCNA, MRPS22 | GPR119 4287/4885ACHE 3345/4885POLB 333/4885 |
| US-20040072829-A1 | Piperazinyltriazines as estrogen receptor modulators | GPER1, ESR2, ESR1 | GPR119 331/4885ACHE 2368/4885POLB 3259/4885 |
| US-20230212164-A1 | ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER | RSU1, KRAS, NRAS | GPR119 3231/4885ACHE 3804/4885POLB 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.